Cargando…
Therapeutic effects of thalidomide in myeloma are associated with the expression of fibroblast growth factor receptor 3
Thalidomide (Thal), a novel agent in the treatment of multiple myeloma, is presumed to act through a variety of mechanisms. In the present study, we examined the relationship between fibroblast growth factor receptor 3 (FGFR3) expression and the therapeutic effect of Thal. The DNA synthesis of KMS-1...
Autores principales: | Qian, Shenxian, Somlo, George, Zhou, Bingsen, Yen, Yun |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1661623/ https://www.ncbi.nlm.nih.gov/pubmed/18360564 |
Ejemplares similares
-
Thalidomide for the Treatment of Refractory Multiple Myeloma: Association of Plasma Concentrations of Thalidomide and Angiogenic Growth Factors with Clinical Outcome
por: Kakimoto, Tsunayuki, et al.
Publicado: (2002) -
Thalidomide and its analogues in the treatment of Multiple Myeloma
por: Latif, Tahir, et al.
Publicado: (2012) -
Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007) -
Adverse Effects of Thalidomide Administration, in Patients with Myeloma Multiplex?
por: Svetlana Balkanov, Krstevska, et al.
Publicado: (2014) -
The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
por: Kim, Cheolsu, et al.
Publicado: (2015)